{"entity":{"id":"pasritamig","kind":"drug","name":"Pasritamig","aka":[],"tldr":"Pasritamig is Johnson & Johnson's bispecific T-cell engager that binds KLK2 on prostate cancer cells and CD3 on T cells, with a deliberately low-affinity CD3 arm. In phase 1 about 40% of patients had a PSA50 response with far less cytokine release syndrome than other engagers, and a phase 3 trial began in 2025.","summary":"Pasritamig (JNJ-78278343) is a bispecific T-cell engager that binds KLK2 on prostate cancer cells and CD3 on T cells; a deliberately low-affinity CD3 arm limits cytokine release so that it can be given in the outpatient setting. It is being developed for metastatic castration-resistant prostate cancer after an androgen receptor pathway inhibitor, with or without a prior taxane. In phase 1, about 40% of patients achieved a PSA50 response at the recommended dose, with cytokine release syndrome rates far below other engagers, and the phase 3 KLK2-P3-01 trial began in 2025. Whether PSA responses will translate into radiographic and survival benefit, and how durable responses are, remain open. For a newcomer, it is Johnson & Johnson's prostate-specific T-cell engager, notable for how little cytokine storm it caused in early trials.","status":"phase-3","asOf":"2026-09-06","links":[{"label":"ClinicalTrials.gov: trials of Pasritamig","url":"https://clinicaltrials.gov/search?intr=JNJ-78278343"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["t-cell-engager"],"targets":["klk2","cd3"],"drugs":[],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":["crs"],"trials":["nct07225946"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"JNJ-78278343","modality":"Bispecific T-cell engager (KLK2×CD3)","mechanism":"Low-affinity CD3 arm and KLK2 targeting; designed for outpatient dosing.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pasritamig/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"term":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"}],"trial":[{"id":"nct07225946","kind":"trial","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07225946/"}]}}